CORRECTION article

Front. Immunol., 05 March 2025

Sec. Multiple Sclerosis and Neuroimmunology

Volume 16 - 2025 | https://doi.org/10.3389/fimmu.2025.1571978

Corrigendum: Blood biomarker dynamics in people with relapsing multiple sclerosis treated with cladribine tablets: results of the 2-year MAGNIFY-MS study

  • 1. Department of Neurology, Institute of Translational Neurology, University of Münster, Münster, Germany

  • 2. Department of Radiology and Nuclear Medicine, Amsterdam UMC, Vrije Universiteit, Amsterdam, Netherlands

  • 3. Queen Square Institute of Neurology and Centre for Medical Image Computing, University College London, London, United Kingdom

  • 4. Department of Neurology-Neuroimmunology, Centre d’Esclerosi Múltiple de Catalunya (Cemcat), Hospital Universitario Vall d’Hebron, Barcelona, Spain

  • 5. Multiple Sclerosis Center, Sheba Academic Medical Center, Ramat Gan, Israel

  • 6. Faculty of Medicine, Tel-Aviv University, Tel-Aviv, Israel

  • 7. Department of Neurology, University Hospital Basel, Basel, Switzerland

  • 8. Department of Neurology, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland

  • 9. Ingham Institute for Applied Medical Research, University of New South Wales Medicine and Liverpool Hospital, Sydney, NSW, Australia

  • 10. Department of Neurosciences, Université de Montréal, Montréal, QC, Canada

  • 11. Department of Neurology, University Vita-Salute San Raffaele, Milan, Italy

  • 12. Experimental Neurophysiology Unit, Scientific Institute IRCCS San Raffaele, Milan, Italy

  • 13. Department of Neurorehabilitation Science, Casa di Cura Igea, Milan, Italy

  • 14. The Blizard Institute, Centre for Neuroscience, Surgery and Trauma, Barts and The London School of Medicine and Dentistry, Queen Mary University of London, London, United Kingdom

  • 15. Clinical Board Medicine (Neuroscience), The Royal London Hospital, Barts Health NHS, Trust, London, United Kingdom

  • 16. Danish MS Center, Department of Neurology, Copenhagen University Hospital - Rigshospitalet, Glostrup, Denmark

  • 17. Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark

  • 18. Univ. Lille, Inserm U1172 LilNCog, CHU Lille, FHU Precise, Lille, France

  • 19. Clinical Measurement Sciences, Merck Healthcare KGaA, Darmstadt, Germany

  • 20. Clinical Research Services, Cytel Inc., Geneva, Switzerland

  • 21. Clinical Measurement Sciences, EMD Serono Research & Development Institute, Inc., an affiliate of Merck KGaA, Billerica, MA, United States

  • 22. Neurology & Immunology Medical Unit, EMD Serono Research & Development Institute, Inc., an affiliate of Merck KGaA, Billerica, MA, United States

  • 23. Department of Medicine, Surgery and Neuroscience, University of Siena, Siena, Italy

Article metrics

View details

2

Citations

1,6k

Views

492

Downloads

In the published article, there was an error in Figure 5 as published. In the figure, the legend for the blue and red dots incorrectly read as “|FC| <1.2 & FDR>0.05”. The legend for blue should read “|FC| <1.2 & FDR<0.05” and for red should read “|FC| >1.2 & FDR<0.05”. The corrected Figure 5 and its caption “Gene expression of CD3+ and CD19+ cells at M12, M15 and M24 compared to BL. BL, baseline; FC, fold change; FDR, false discovery rate; M, month.” appear below.

Figure 5

The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

Statements

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Summary

Keywords

multiple sclerosis, cladribine tablets, biomarkers, transcriptomics, immunophenotyping, immune reconstitution therapy

Citation

Wiendl H, Barkhof F, Montalban X, Achiron A, Derfuss T, Chan A, Hodgkinson S, Prat A, Leocani L, Schmierer K, Sellebjerg F, Vermersch P, Jin H, Chudecka A, Kloetgen A, Lin D, Gardner L and De Stefano N (2025) Corrigendum: Blood biomarker dynamics in people with relapsing multiple sclerosis treated with cladribine tablets: results of the 2-year MAGNIFY-MS study. Front. Immunol. 16:1571978. doi: 10.3389/fimmu.2025.1571978

Received

06 February 2025

Accepted

24 February 2025

Published

05 March 2025

Volume

16 - 2025

Edited and reviewed by

Klaus Berek, Innsbruck Medical University, Austria

Updates

Copyright

*Correspondence: Heinz Wiendl,

†Present address: Heinz Wiendl, Department of Neurology and Neurophysiology, Freiburg University, Freiburg, Germany

Disclaimer

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

Outline

Figures

Cite article

Copy to clipboard


Export citation file


Share article

Article metrics